Skin and Connective Tissue Diseases

445 trials 165 recruiting

Filter these 445 trials by phase, country and sponsor.

Open in Search →

A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers … Recruiting

2025-521658-40-00 Atopic dermatitis 1 2025-10-27
A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s… Recruiting

2024-519623-23-00 Venous leg ulcer 5 2025-10-20
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting

2024-519795-11-00 Atopic Dermatitis 4 2025-10-06
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
A study to test if difelikefalin is safe in adolescents with itching related to long term kidney disease Recruiting

2023-509909-74-00 Pruritus 4 2025-08-13
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-… Recruiting

2024-511346-39-00 Immune-mediated necrotizing myopathy 3 2025-03-28
TAR-0520 gel in EGFR inhibitor-induced folliculitis Recruiting

2024-516339-28-00 EGFR inhibitor-induced folliculitis 4 2025-02-10
Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding… Recruiting

2024-518368-10-00 Recessive dystrophic epidermolysis bullosa (RDEB) 7 2025-01-29
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Prurigo Nodularis 5 2024-12-12
A multicentre, intra-patient randomised controlled Phase III study to confirm the efficacy and safety of denovoSkin™, a bilayer engineered c… Recruiting

2023-507717-94-00 Deep partial and full-thickness burns 5 2024-12-06
Belimumab in SLE Recruiting

2024-518966-28-00 Systemic lupus erythematodes 6 2024-11-25
A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag… Recruiting

2023-503630-44-00 Treatment of moderate-to-severe Atopic dermatitis 10 2024-11-20
Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Pat… Recruiting

2023-507536-21-00 Advanced Solid Tumors 7 2024-10-04
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formu… Recruiting

2023-510017-26-00 Completely Resected Stage IIB, IIC, and III Melanoma 1 2024-10-02
A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versu… Recruiting

2023-507470-40-00 Vitiligo 10 2024-08-27
Efficacy of nasal oxygen therapy on the reduction of postoperative complications in ankle trauma surgery in at-risk patients: a randomized p… Recruiting

2024-516578-31-00 Oxygen therapy in trauma ankle surgery patients 5 2024-08-21
A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 1… Recruiting

2023-508099-12-00 Dermatitis atopic 5 2024-06-20
A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immun… Recruiting

2023-508661-33-00 Rheumatoid Arthritis 1 2024-05-29
Efficacy, safety, tolerability, and pharmacokinetics of risankizumab in pediatric subjects with active juvenile psoriatic arthritis Recruiting

2023-506026-36-00 Juvenile Psoriatic Arthritis 5 2024-04-29
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants with HPP Recruiting

2023-505675-73-00 hypophosphatasia 5 2024-04-26
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Ato… Recruiting

2022-501478-21-00 Atopic Dermatitis Eczema 5 2024-03-15
Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANE Recruiting

2023-505945-19-00 stage II melanoma 4 2024-03-08
Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting

2022-500266-10-00 Recessive Dystrophic Epidermolysis Bullosa(RDEB) and Ju 5 2023-06-13